E
Humacyte, Inc.
HUMA
$3.16
$0.154.98%
E
Sell
3/17/2025Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 3/17/2025 due to a decline in the volatility index and total return index.
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 3/17/2025 due to a decline in the volatility index and total return index.
D
Sell
2/24/2025Upgraded
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 2/24/2025 due to an increase in the volatility index and valuation index.
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 2/24/2025 due to an increase in the volatility index and valuation index.
E
Sell
2/6/2025Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 2/6/2025 due to a decline in the volatility index.
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 2/6/2025 due to a decline in the volatility index.
D
Sell
1/22/2025Upgraded
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 1/22/2025 due to an increase in the volatility index.
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 1/22/2025 due to an increase in the volatility index.
E
Sell
1/7/2025Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 1/7/2025 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 5.27 to 0.98, and debt to equity increased from -2.23 to -1.02.
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 1/7/2025 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 5.27 to 0.98, and debt to equity increased from -2.23 to -1.02.
D
Sell
8/15/2024Upgraded
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 8/15/2024 due to an increase in the valuation index, growth index and total return index. Operating cash flow increased 22.15% from -$27.35M to -$21.29M.
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 8/15/2024 due to an increase in the valuation index, growth index and total return index. Operating cash flow increased 22.15% from -$27.35M to -$21.29M.
E
Sell
7/19/2024Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 7/19/2024 due to a decline in the valuation index.
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 7/19/2024 due to a decline in the valuation index.
D
Sell
6/17/2024Upgraded
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 6/17/2024 due to an increase in the total return index and volatility index.
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 6/17/2024 due to an increase in the total return index and volatility index.
E
Sell
5/29/2024Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 5/29/2024 due to a decline in the valuation index.
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 5/29/2024 due to a decline in the valuation index.
D
Sell
5/14/2024Upgraded
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 5/14/2024 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 4.36 to 8.2, and debt to equity declined from 0.19 to 0.1.
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 5/14/2024 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 4.36 to 8.2, and debt to equity declined from 0.19 to 0.1.
E
Sell
3/28/2024Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 3/28/2024 due to a decline in the solvency index, growth index and efficiency index. Debt to equity increased from 0.07 to 0.19, operating cash flow declined 46.49% from -$13.01M to -$19.05M, and total capital declined 42.55% from $56.49M to $32.45M.
Humacyte, Inc. (HUMA) was downgraded to E+ from D- on 3/28/2024 due to a decline in the solvency index, growth index and efficiency index. Debt to equity increased from 0.07 to 0.19, operating cash flow declined 46.49% from -$13.01M to -$19.05M, and total capital declined 42.55% from $56.49M to $32.45M.
D
Sell
8/15/2023Upgraded
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 8/15/2023 due to an increase in the total return index, volatility index and efficiency index. Net income increased 38.58% from -$36.97M to -$22.71M.
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 8/15/2023 due to an increase in the total return index, volatility index and efficiency index. Net income increased 38.58% from -$36.97M to -$22.71M.
E
Sell
3/27/2023Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 3/27/2023 due to a substantial decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 9.59 to 7.76, debt to equity increased from 0.26 to 0.27, and total capital declined 1.14% from $169.56M to $167.63M.
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 3/27/2023 due to a substantial decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 9.59 to 7.76, debt to equity increased from 0.26 to 0.27, and total capital declined 1.14% from $169.56M to $167.63M.
D
Sell
8/15/2022Upgraded
Humacyte, Inc. (HUMA) was upgraded to D from D- on 8/15/2022 due to a significant increase in the efficiency index, growth index and valuation index. Total revenue increased 458.37% from $233 to $1.3M, net income increased 285.9% from -$19.83M to $36.87M, and earnings per share increased from -$0.1925 to $0.35.
Humacyte, Inc. (HUMA) was upgraded to D from D- on 8/15/2022 due to a significant increase in the efficiency index, growth index and valuation index. Total revenue increased 458.37% from $233 to $1.3M, net income increased 285.9% from -$19.83M to $36.87M, and earnings per share increased from -$0.1925 to $0.35.
D
Sell
5/16/2022Upgraded
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index and total return index.
Humacyte, Inc. (HUMA) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index and total return index.
E
Sell
5/13/2022Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
Humacyte, Inc. (HUMA) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
Humacyte, Inc. (HUMA) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
E
Sell
5/1/2022Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Humacyte, Inc. (HUMA) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
Humacyte, Inc. (HUMA) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 04/20/2022.
Humacyte, Inc. (HUMA) was downgraded to E+ from D on 04/20/2022.
D
Sell
4/18/2022Upgraded
Humacyte, Inc. (HUMA) was upgraded to D from D- on 4/18/2022 due to an increase in the solvency index, total return index and volatility index.
Humacyte, Inc. (HUMA) was upgraded to D from D- on 4/18/2022 due to an increase in the solvency index, total return index and volatility index.
D
Sell
3/31/2022Downgrade
Humacyte, Inc. (HUMA) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the total return index, efficiency index and volatility index.
Humacyte, Inc. (HUMA) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the total return index, efficiency index and volatility index.
D
Sell
11/18/2021Downgrade
Humacyte, Inc. (HUMA) was downgraded to D from D+ on 11/18/2021 due to a decline in the valuation index and growth index. Operating cash flow declined 107.9% from -$14.68M to -$30.52M, total revenue declined 65.07% from $690 to $241, and EBIT declined 6.61% from -$19.27M to -$20.54M.
Humacyte, Inc. (HUMA) was downgraded to D from D+ on 11/18/2021 due to a decline in the valuation index and growth index. Operating cash flow declined 107.9% from -$14.68M to -$30.52M, total revenue declined 65.07% from $690 to $241, and EBIT declined 6.61% from -$19.27M to -$20.54M.
D
Sell
11/3/2021None
Humacyte, Inc. (HUMA) was downgraded to D+ from U on 11/03/2021.
Humacyte, Inc. (HUMA) was downgraded to D+ from U on 11/03/2021.
NASDAQ
03/18/2025 11:00AM Eastern
Quotes delayed
